PMC:7532132 / 16475-17796 JSONTXT

{"project":"2_test","denotations":[{"id":"33006710-11055295-28310","span":{"begin":674,"end":676},"obj":"11055295"},{"id":"33006710-27703593-28311","span":{"begin":1199,"end":1201},"obj":"27703593"}],"text":"Later, the effect of different concentrations of PVA on particle size was investigated. SEM images indicate that formulation containing 7.5% (w/v) of PVA presents particle diameter of 30.05 ± 3.43 μm, a 1.38-fold increase (p \u003c 0.0001) with respect to particles obtained with 5.0% % (w/v) of PVA with an average diameter of 21.68 ± 4.09 μm. Even if PVA usually reduces drug particle size when used as a single polymer, it is well known that it causes drug particle growth when combined with other polymers (41,42). In this study, PVA and PHEA combination lead to obtaining an overall particle diameter that was smaller than 200 μm, reported to be typical of PVA formulation (43). Particularly, increased particle size could be due to salting out of sodium increasing interaction between ibuprofen molecules. This event is recognized as happening when two soluble polymers are dissolved at higher concentration (44). Figure 4 shows SEM images of F5 and F6 of samples with two different magnifications. For each formulation, PDI was calculated and found to be respectively 1.08 and 1.12. This result shows that the drug was not monodispersed due to formation of aggregate that is noticeable in Fig. 4 (45).\nFig. 4 SEM images of F5 with a magnification of a × 350 and b × 700 and F6 with a magnification of c × 1K and d × 900"}